What is HC Wainwright’s Forecast for ENTA Q2 Earnings?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for Enanta Pharmaceuticals in a note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will earn ($1.42) per share for the quarter, down from their previous estimate of ($1.32). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($5.05) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

Several other research firms have also weighed in on ENTA. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Robert W. Baird lowered their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Up 4.8 %

NASDAQ ENTA opened at $5.86 on Thursday. The firm’s fifty day moving average price is $5.80 and its two-hundred day moving average price is $9.54. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Krensavage Asset Management LLC increased its position in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after purchasing an additional 246,736 shares during the period. Erste Asset Management GmbH acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $1,243,000. Point72 Asset Management L.P. bought a new position in Enanta Pharmaceuticals in the 3rd quarter valued at about $903,000. JPMorgan Chase & Co. raised its position in shares of Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after buying an additional 85,082 shares in the last quarter. Finally, Trexquant Investment LP lifted its holdings in shares of Enanta Pharmaceuticals by 97.3% during the 4th quarter. Trexquant Investment LP now owns 135,954 shares of the biotechnology company’s stock worth $782,000 after acquiring an additional 67,040 shares during the period. Institutional investors own 94.99% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 13.89% of the stock is currently owned by insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.